Evaluating new genomic tests for disease management and screening
BUILDING THE EVIDENCE BASE FOR APPROPRIATE AND EFFICIENT IMPLEMENTATION OF EMERGING GENOMIC TESTS FOR DISEASE MANAGEMENT AND SCREENING
This study is looking at new genetic tests that can help catch diseases early and improve treatment, and it wants to find out how insurance companies decide if they will cover these tests so that more patients can benefit from them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11078714 on NIH RePORTER |
What this research studies
This research investigates the implementation of emerging genomic tests, specifically cell-free DNA tests and polygenic risk scores, to improve disease management and early detection. It aims to understand how insurance payers decide on coverage for these tests and assess their economic value from a patient-centered perspective. The study will involve systematic reviews of payer policies and interviews with payers to gather insights on evidence requirements. By addressing these factors, the research seeks to enhance patient access to potentially life-saving genomic testing.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients at risk for atherosclerotic coronary disease and cancers who may benefit from genomic testing for early detection.
Not a fit: Patients who do not have a risk for the targeted conditions or those who are already symptomatic may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved access to genomic tests that enhance early detection and management of diseases, ultimately benefiting patient outcomes.
How similar studies have performed: Other research has shown success in evaluating genomic tests for clinical use, indicating that this approach is both relevant and necessary.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Phillips, Kathryn a — University of California, San Francisco
- Study coordinator: Phillips, Kathryn a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.